EBITDA: Income before interest, taxes, depreciation and amortization.
XTL Biopharmaceuticals Ltd. (XTLB) had EBITDA of $-0.77M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-1.78M |
|
-- |
|
-- |
|
$0.77M |
|
$-0.77M |
|
$-1.02M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-1.78M |
|
$-0.77M |
|
|
EBITDA |
$-0.77M |
5.45M |
|
5.45M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$2.05M |
|
-- |
|
$0.38M |
|
$2.43M |
|
$0.21M |
|
-- |
|
-- |
|
$0.21M |
|
$2.22M |
|
$1.84M |
|
$2.22M |
|
5.45M |
|
| Cash Flow Statement Financials | |
$-0.71M |
|
$0.04M |
|
-- |
|
$2.09M |
|
$1.40M |
|
$-0.69M |
|
$0.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-80.27% |
|
-96.85% |
|
-73.45% |
|
-80.27% |
|
$0.41 |
|
$-0.13 |
|
$-0.13 |
|